India conducts more than 5 lakh Covid-19 test in a single day


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ India conducts more than 5 lakh Covid-19 test in a single day
More than 5 lakh tests conducted for second consecutive day, 10 lakh in coming weeks

India has conducted more than five lakh COVID-19 tests in a single day over two consecutive days. Union Health Ministry said this is the outcome of the combined and focused efforts of Centre, State and Union Territories governments on aggressive testing. During the last 24 hours, India tested a total of 5,15000 samples. Testing is the first important step in the early detection and isolation of COVID-19 positive cases.

The graded and evolving response resulted in a testing strategy that steadily widened the testing network in the country, and the cumulative testing has crossed 1,73,00000.

The Tests Per Million has further improved to 12,562. Health Ministry said, the testing capacity of India has received another boost with the induction of three high throughput testing facilities in Noida, Mumbai and Kolkata that were inaugurated virtually.

The testing lab network in the country has been strengthened with  1310 labs in the country, 905 labs in the government sector and 405 private labs.

Meanwhile, the human clinical trials of potential Covid-19 vaccine called COVAXIN has started at AIIMS, New Delhi. The first dose was given to a 30-year-old man in AIIMS-Delhi yesterday.

Indian Council of Medical Research and Bharat Biotech have joined hands for the development of 'Covaxin'. AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research for conducting phase I and II human trials of COVAXIN. In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.

Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomized, double-blind, placebo-controlled clinical trial.

Tags : #IndiaCovidUpdate #ICMR #IIMS #COVAXIN #BharatBiotech #CovaxinTrial

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026